XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Summary of Common Stock Reserved for Future Issuance

Shares of our common stock reserved for future issuance as of December 31, 2020 were as follows:

 

 

 

Number of

 

 

 

Shares

 

Stock options outstanding

 

 

18,912,529

 

Restricted stock units outstanding

 

 

602,741

 

Stock options available for grant

 

 

1,575,955

 

Employee Stock Purchase Plan

 

 

176,250

 

Warrants outstanding

 

 

220,164

 

Shares of common stock underlying Convertible Notes outstanding (see Note 8)

 

 

9,510,208

 

Total shares reserved for future issuance

 

 

30,997,847

 

 

Summary of Stock Option Plan Activity (Including Restricted Stock Units)

The following table summarizes the stock option plan activity (including RSUs):

 

 

 

Outstanding Options

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

Average

 

 

 

Number of

 

 

Exercise

 

 

 

Shares

 

 

Price

 

Balance at December 31, 2017

 

 

13,462,964

 

 

$

15.03

 

Granted

 

 

4,052,011

 

 

$

26.83

 

Exercised

 

 

(1,529,509

)

 

$

11.97

 

Cancelled

 

 

(720,859

)

 

$

17.98

 

Balance at December 31, 2018

 

 

15,264,607

 

 

$

18.33

 

Granted

 

 

4,933,480

 

 

$

24.21

 

Exercised

 

 

(1,983,221

)

 

$

11.18

 

Cancelled

 

 

(1,550,226

)

 

$

23.26

 

Balance at December 31, 2019

 

 

16,664,640

 

 

$

20.47

 

Granted

 

 

4,659,942

 

 

$

13.95

 

Exercised

 

 

(544,441

)

 

$

12.41

 

Cancelled

 

 

(1,264,871

)

 

$

22.84

 

Balance at December 31, 2020

 

 

19,515,270

 

 

$

18.98

 

 

Schedule of Options Exercisable, Vested or Expected to Vest

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

Average

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

Exercise

 

 

 

Options

 

 

Price

 

 

Options

 

 

Price

 

 

Options

 

 

Price

 

Exercisable at end of year

 

 

10,237,202

 

 

$

18.74

 

 

 

7,436,379

 

 

$

17.02

 

 

 

6,523,093

 

 

$

14.83

 

Options vested or expected to vest

 

 

18,179,553

 

 

$

19.58

 

 

 

15,962,432

 

 

$

20.31

 

 

 

14,449,017

 

 

$

18.11

 

 

 

Schedule of Exercise Prices And Weighted-average Remaining Contractual Lives For Options Outstanding

Exercise prices and weighted-average remaining contractual lives for the options outstanding as of December 31, 2020 were:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Average

 

 

Weighted-

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

 

Remaining

 

 

Average

 

 

 

 

 

 

Price of

 

Options

 

 

Range of

 

Contractual

 

 

Exercise

 

 

Options

 

 

Options

 

Outstanding

 

 

Exercise Prices

 

Life (in years)

 

 

Price

 

 

Exercisable

 

 

Exercisable

 

 

2,700,473

 

 

$5.20–$13.00

 

 

3.97

 

 

$

10.14

 

 

 

2,691,327

 

 

$

10.14

 

 

800,371

 

 

$13.05–$15.55

 

 

6.13

 

 

 

14.31

 

 

 

655,173

 

 

 

14.22

 

 

3,582,407

 

 

$15.72

 

 

9.75

 

 

 

15.72

 

 

 

149,197

 

 

 

15.72

 

 

2,838,033

 

 

$15.78–$17.89

 

 

6.10

 

 

 

16.87

 

 

 

2,348,090

 

 

 

16.84

 

 

3,688,255

 

 

$18.00–$24.97

 

 

7.15

 

 

 

22.97

 

 

 

2,036,430

 

 

 

23.10

 

 

3,498,912

 

 

$25.02

 

 

8.63

 

 

 

25.02

 

 

 

1,010,859

 

 

 

25.02

 

 

1,804,078

 

 

$25.06–$39.00

 

 

6.64

 

 

 

30.58

 

 

 

1,346,126

 

 

 

30.43

 

 

18,912,529

 

 

 

 

 

7.21

 

 

 

19.59

 

 

 

10,237,202

 

 

 

18.74

 

 

Summary of Stock-Based Compensation Expense related to Stock-Based Payment Awards

The following table summarizes stock-based compensation expense related to stock-based payment awards pursuant to our equity compensation arrangements (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Research and development

 

$

20,731

 

 

$

19,202

 

 

$

13,689

 

General and administrative

 

 

15,601

 

 

 

13,564

 

 

 

9,630

 

Sales and marketing

 

 

13,886

 

 

 

18,645

 

 

 

10,048

 

Total stock-based compensation expense

 

$

50,218

 

 

$

51,411

 

 

$

33,367

 

 

Summary of Fair Value of Option Grant and ESPP Purchase Right on Grant Date Using Black-Scholes Option Pricing Model

We estimated the fair value of each option grant and ESPP purchase right on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

Options:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Risk-free interest rate

 

 

0.5

%

 

 

1.8

%

 

 

2.8

%

Dividend yield

 

 

%

 

 

%

 

 

%

Volatility

 

 

69.4

%

 

 

66.5

%

 

 

70.4

%

Expected life (years)

 

 

6

 

 

 

6

 

 

 

6

 

 

 

ESPP:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Risk-free interest rate

 

 

0.1

%

 

 

1.9

%

 

 

2.4

%

Dividend yield

 

 

%

 

 

%

 

 

%

Volatility

 

 

67.7

%

 

 

52.1

%

 

 

59.7

%

Expected life (months)

 

 

6

 

 

 

6

 

 

 

6